Immune-mediated thrombocytopenia (IMT) causes dangerously low platelet counts in dogs, creating bleeding risks and requiring immunosuppressive treatment with significant welfare implications.
IMT causes welfare compromise through the constant threat of spontaneous bleeding that creates anxiety in owners and requires careful activity restriction in affected dogs. Mucosal bleeding is visible and distressing; internal hemorrhage is less visible but potentially life-threatening. The immune-mediated nature of the condition means immunosuppressive therapy is required, with associated side effects including increased thirst, urination, panting, and susceptibility to infection. The uncertainty of response to treatment creates a period of significant welfare risk while awaiting platelet count recovery. Dogs that respond well to treatment can return to normal activity, but the monitoring burden and medication side effects during treatment represent ongoing welfare considerations. Coexisting conditions like IMHA (Evans' syndrome) worsen prognosis and welfare outlook significantly.